-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Three projects of Guangxiang Pharmaceutical, part of Shijiazhuang Sihua Pharmaceutical Group, have been selected as major science and technology special projects and science and technology program projects of Cangzhou City, respectively.
Category:
TIME：2025-01-15
Recently, three technological advancement and industrialization projects of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, were selected as major science and technology special projects and science and technology program projects by Cangzhou City, which will further accelerate the company’s technological upgrading and product innovation, and provide policy support for the ongoing drive to elevate products toward high-end, branded, and green development.
Among the selected projects, “R&D and Industrialization of the Active Pharmaceutical Ingredient Penthoxifylline” has been approved as a Major Science and Technology Special Project for Cangzhou City for the 2023–2024 period; “Mechanism of Accumulation and Control of Genotoxic Impurities in a Novel Synthesis Process for Butylphenol Based on the Full Life Cycle” has been approved as a Municipal Natural Science Fund Project; and “Optimization of the Chiral Synthesis Process of Procaterol Based on Artificial Intelligence and Its Application Expansion” has been approved as a Key Municipal Science and Technology Project under the “Challenge-Based Recruitment” initiative.
As a high-value-added active pharmaceutical ingredient, theophylline raw material has long posed significant challenges to the industry due to low purity, high production costs, and substantial environmental compliance pressures in conventional manufacturing processes. Guided by these issues, Guangxiang Pharmaceutical has focused on breakthroughs in key technologies—including condensation reactions, intermediate purification, and environmentally friendly wastewater treatment—and has achieved notable results, securing two authorized invention patents and one utility model patent.
Butylphthalide is a synthetic compound indicated for the treatment of mild to moderate acute ischemic stroke. Based on research into the synthetic route of butylphthalide, Guangxiang Pharmaceutical has continuously conducted systematic analytical studies on potential genotoxic impurities that may be introduced, thereby defining the impurity profile, elucidating their sources, accumulation mechanisms, and control strategies. These efforts provide a theoretical basis for the analysis of trace-level genotoxic impurities and for the development of relevant pharmaceutical standards, thus ensuring the safety and efficacy of the drug.
Procaterol is a third-generation adrenergic agent, and conventional manufacturing methods are cumbersome and costly. Leveraging a collaborative innovation model involving industry, academia, and research institutions, Guangxiang Pharmaceutical has partnered with renowned universities to conduct integrated research on AI and asymmetric synthesis technologies, thereby optimizing the production process for chiral drugs, enhancing the manufacturing efficiency of procaterol and other chiral alcohol-based pharmaceuticals, reducing production costs, and ultimately strengthening the market competitiveness of its products.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
